Michael Untch

72.5k total citations · 8 hit papers
542 papers, 19.7k citations indexed

About

Michael Untch is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Untch has authored 542 papers receiving a total of 19.7k indexed citations (citations by other indexed papers that have themselves been cited), including 385 papers in Oncology, 318 papers in Cancer Research and 170 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Untch's work include Breast Cancer Treatment Studies (284 papers), HER2/EGFR in Cancer Research (191 papers) and Cancer Treatment and Pharmacology (179 papers). Michael Untch is often cited by papers focused on Breast Cancer Treatment Studies (284 papers), HER2/EGFR in Cancer Research (191 papers) and Cancer Treatment and Pharmacology (179 papers). Michael Untch collaborates with scholars based in Germany, United States and Switzerland. Michael Untch's co-authors include Gϋnter von Minckwitz, Sibylle Loibl, Christian Jackisch, Jens Huober, Gottfried E. Konecny, Jens‐Uwe Blohmer, Peter A. Fasching, Valentina Nekljudova, Ingo Bauerfeind and Carsten Denkert and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Untch

523 papers receiving 19.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

2013 928 citations Tanja Fehm, Barbara Fleige et al. profile →
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

2006 711 citations Gottfried E. Konecny, Mark D. Pegram et al. Cancer Research profile →
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

2017 688 citations Michael Untch, Christian Jackisch et al. profile →
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

2006 548 citations Gabriel N. Hortobágyi, Annette Lebeau et al. Journal of Clinical Oncology profile →
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

2018 516 citations Sibylle Loibl, Joyce O’Shaughnessy et al. profile →
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. Annals of Oncology profile →
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Michael Untch

Since Specialization

Citations

This map shows the geographic impact of Michael Untch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Untch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Untch more than expected).

Fields of papers citing papers by Michael Untch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Untch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Untch. The network helps show where Michael Untch may publish in the future.

Co-authorship network of co-authors of Michael Untch

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Untch. A scholar is included among the top collaborators of Michael Untch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Untch. Michael Untch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial 2025 ·Clinical Cancer Research ·Peter A. Fasching, Dennis J. Slamon, Zbigniew Nowecki, (unknown), Daniil Stroyakovskiy, DA Yardley, Chiun‐Sheng Huang, Arlene Chan, Stephen Chia, Miguel Martín, Hope S. Rugo, Sherene Loi, Sara A. Hurvitz, Michael Untch, Karen Afenjar, Rodrigo Fresco, Andriy Danyliv, (unknown), (unknown), Gabriel N. Hortobágyi	2
2	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 breakdown → 2024 ·Annals of Oncology ·Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy, Javier Cortés, Rebecca Dent, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Y.H. Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fátima Cardoso, Ying Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid	47
3	Discussion of ABC7 Consensus and German Recommendations 2024 ·Geburtshilfe und Frauenheilkunde ·Michael Untch, Nina Ditsch, Peter A. Fasching, Steffi Busch, Johannes Ettl, Renate Haidinger, Nadia Harbeck, Christian Jackisch, Diana Lüftner, Lothar Müller, Eugen Ruckhäberle, Eva Schumacher-Wulf, Christoph Thomssen, Rachel Wuerstlein, Volkmar Müller	1
4	Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial 2024 ·The Lancet Regional Health - Europe ·Alexios Matikas, Andri Papakonstantinou, Sibylle Loibl, Günther Steger, Michael Untch, Hemming Johansson, Nikos Tsiknakis, Mats Hellström, Richard Greil, Volker Möbus, Michael Gnant, Jonas Bergh, Theodoros Foukakis	2
5	Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041) 2023 ·European Journal of Cancer ·Peter A. Fasching, Alexander Hein, Hans‐Christian Kolberg, Lothar Häberle, (unknown), Matthias Rübner, Erik Belleville, Carolin C. Hack, Tanja Fehm, (unknown), Arndt Hartmann, Ramona Erber, (unknown), Sara Y. Brucker, Andreas D. Hartkopf, Michael Untch	25
6	Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial 2023 ·European Journal of Cancer ·Marcus Schmidt, Ulrike Nitz, Toralf Reimer, Sabine Schmatloch, Heiko Graf, Marianne Just, Elmar Stickeler, Michael Untch, Ingo B. Runnebaum, Antje Belau, Jens Huober, Christian Jackisch, Manfred Hofmann, (unknown), Valentina Nekljudova, Sibylle Loibl	1
7	Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients 2022 ·European Journal of Cancer ·Marion van Mackelenbergh, Fenja Seither, Volker Möbus, Joyce O’Shaughnessy, Miguel Martín, Heikki Joensuu, Michael Untch, Ulrike Nitz, Guenther G. Steger, J. Miralles, Carlos H. Barrios, Masakazu Toi, Harry D. Bear, Hyman B. Muss, Toralf Reimer, Valentina Nekljudova, Sibylle Loibl	9
8	Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE 2022 ·npj Breast Cancer ·Sibylle Loibl, Chiun‐Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean‐Christophe Théry, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark	22
9	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis 2020 ·Cancer Research ·Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortés, Scott D. Ramsey, Andrew Briggs, (unknown), Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, (unknown), John S. Cook, Michael Untch, Peter Schmid, Peter A. Fasching	89
10	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial 2017 ·Clinical Cancer Research ·Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, J. Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gϋnter von Minckwitz, Michael Untch, Klaus Pantel	82
11	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer 2016 ·Clinical Cancer Research ·Sibylle Loibl, Silvia Darb‐Esfahani, Jens Huober, Alexander C. Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit M. Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gϋnter von Minckwitz, Michael Untch, Carsten Denkert	34
12	Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data 2015 ·Modern Pathology ·Oliver Stoß, Andreas H. Scheel, Iris Nagelmeier, Hans‐Ulrich Schildhaus, Thomas Henkel, Giuseppe Viale, Bharat Jasani, Michael Untch, Josef Rüschoff	42
13	What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? 2012 ·PubMed ·(unknown), Sibylle Loibl, Michael Untch	19
14	Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study 2010 ·Journal of Clinical Oncology ·Volker Moebus, Christian Jackisch, Hans-Joachim Lueck, Andreas du Bois, Christoph Thomssen, Christian M. Kurbacher, Walther Kuhn, Ulrike Nitz, Andreas Schneeweiß, Jens Huober, Nadia Harbeck, Gϋnter von Minckwitz, Ingo B. Runnebaum, Axel Hinke, R. Kreienberg, Gottfried E. Konecny, Michael Untch	126
15	Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies 2010 ·Journal of Clinical Oncology ·Annette Lebeau, Andreas Turzynski, Susanne Braun, (unknown), Barbara Fleige, Wolfgang Schmitt, Tobias Grob, Lia Burkhardt, D. Hölzel, Christian Jackisch, Christoph Thomssen, Volkmar Müller, Michael Untch	50
16	Anthracycline and trastuzumab in breast cancer treatment. 2004 ·PubMed ·Michael Untch, (unknown), Steffen Kahlert, (unknown), Holger Eidtmann, Andreas du Bois, H.G. Meerpohl, Christoph Thomssen, Nadia Harbeck, C Jackisch, R. Kreienberg, Günter Emons, D. Wallwiener, William H. Wiese, Gerhard Schäller, W. Kühn, M Muscholl, M. Pauschinger, Bernd Langer	6
17	[Sentinel node biopsy in breast cancer]. 2004 ·PubMed ·Thorsten Kühn, A. Bembenek, (unknown), Thomas Decker, Juergen Dunst, U. Müllerleile, D. L. Munz, H. Ostertag, M.-L. Sautter-Bihl, Holger Schirrmeister, A. H. Tulusan, Michael Untch, Klaus‐Jürgen Winzer, Christian Wittekind	2
18	HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer 2004 ·JNCI Journal of the National Cancer Institute ·G. Konecny, (unknown), Hans‐Joachim Lück, Michael Untch, (unknown), W. Kühn, (unknown), (unknown), Suzanne M. Olbricht, (unknown), (unknown), Gϋnter von Minckwitz, Sugandha Dandekar, (unknown), Giovanni M. Pauletti, M. Pegram, (unknown), Dennis J. Slamon	110
19	[Breast scintigraphy using 99mTc-sestamibi--use and limitations]. 2002 ·PubMed ·Reinhold Tiling, R. Linke, Manuel Keßler, Michael Untch, (unknown), Kirsten Brinkbäumer, Ina Becker, Klaus M. Hahn	4
20	Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. 2001 ·PubMed ·Gottfried E. Konecny, Michael Untch, (unknown), Rainer Kimmig, M. Gropp, P Stieber, H. Hepp, Dennis J. Slamon, Mark D. Pegram	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact